BMO Capital analyst Evan Seigerman notes that a U.S. district court issued a ruling in favor of Acadia Pharmaceuticals (ACAD) in their Nuplazid patent infringement lawsuit with Aurobindo, confirming today that Aurobindo infringed on claims 4 and 5 of Acadia’s 11,452,721 U.S. formulation patent. Today’s announcement likely extends the lifespan of pimavanserin and could extend the company’s patent protection from 2030 to 2038, removing a “key overhang,” says the analyst, who reiterates an Outperform rating and $24 price target on Acadia shares.
Kens
BMO Capital analyst Evan Seigerman notes that a U.S. district...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.96 |
Change
0.000(0.00%) |
Mkt cap ! $1.612B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 34 | $14.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.92 | 260 | 1 |
View Market Depth
| Last trade - 09.45am 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable